rs9939609
|
|
Malignant Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
The rs9939609 polymorphism in the FTO gene has recently been implicated as a risk factor for some types of cancer, such as breast, pancreatic, and prostate cancers.
|
29260910 |
2018 |
rs9939609
|
|
Malignant Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
The study objective was to assess the prevalence of cardiovascular disease risk factors in patients treated for childhood cancer (<i>N</i> = 101) and to determine the involvement of clinical (cancer type and therapy) and/or genetic (<i>FTO</i> gene rs9939609 polymorphism) factors.
|
29675043 |
2018 |
rs9939609
|
|
Malignant Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Besides, in the subgroup analysis of ethnicity, our results indicated that rs9939609 polymorphism was significantly associated with cancer risk in Asians.
|
26931363 |
2017 |
rs9939609
|
|
Malignant Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
However, <i>FTO</i> rs9939609 variant was associated with some types of cancer in the subgroup analysis.
|
28881622 |
2017 |
rs9939609
|
|
Malignant Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Variants (such as rs9939609) in the fat mass- and obesity-associated (FTO) gene have been associated with obesity, type 2 diabetes, some cancers, and alcohol consumption.
|
23771786 |
2013 |
rs9939609
|
|
Malignant Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Our meta-analysis indicated that there was no association between FTO rs9939609 polymorphism and the increased risk of c</span>ancer, although this polymorphism was marginally associated with pancreatic cancer.
|
22396042 |
2012 |
rs9939609
|
|
Malignant Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Among 22,799 individuals (44-74 years) in the population-based Malmö diet and cancer cohort that were genotyped for rs9939609 in FTO and had information on dietary intake (from a modified diet history method) and no history of diabetes, cancer or cardiovascular disease, 2255 deaths (including 1100 cancer and 674 cardiovascular deaths) occurred during 12.0 years of follow-up.
|
21179003 |
2011 |
rs9939609
|
|
Malignant Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
The rs9939609 A allele, which was associated with higher BMI in the sample, was inversely associated with overall (odds ratio (OR) versus all controls = 0.93; 95% confidence interval (CI): 0.85-1.02 p = 0.12 per allele) and low-grade (OR = 0.90; 0.81-0.99 p = 0.03 per allele) prostate cancer risk, but positively associated with high-grade cancer among cases (OR high- versus low-grade cancer = 1.16; 0.99-1.37 p = 0.07 per allele).
|
20976066 |
2010 |
rs9939609
|
|
Malignant Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
A cross-sectional study examined 4839 subjects in the population-based Malmö Diet and Cancer study with dietary data (from a modified diet history method) and information on the genetic variant FTO (rs9939609).
|
19726594 |
2009 |
rs1800625
|
|
Malignant Neoplasms
|
|
0.720 |
GeneticVariation
|
BEFREE |
CONCLUSIONS In conclusion, the RAGE rs1800625 polymorphism was associated with increased overall cancer risk in Asians in recessive genetic model.
|
31534114 |
2019 |
rs1800625
|
|
Malignant Neoplasms
|
|
0.720 |
GeneticVariation
|
BEFREE |
Therefore, we performed a systematic review to identify statistical evidence of the association between the 3 polymorphisms rs2070600 G/S (82G>S), rs1800624 T/A ( -374 T>A) and rs1800625C/T (-429 C>T) and the risk of cancer.
|
26011358 |
2015 |
rs1800625
|
|
Malignant Neoplasms
|
|
0.720 |
GeneticVariation
|
BEFREE |
We failed to get an effective conclusion about the association between the rs1800624 and rs1800625 polymorphisms and cancer risk in overall comparison.
|
26011358 |
2015 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
TP53 Arg72Pro (rs1042522 C > G) and miR-34b/c rs4938723 (T > C) polymorphisms have been known to modify cancer susceptibility.
|
31325764 |
2019 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single Nucleotide Polymorphisms (SNPs) of P53 Pro72Arg, MDM2 SNP309, P21 Ser31Arg, ER SNP594, HER2 Ile655Val, and FGFR2 rs2981582 have drawn attention as genetic factors associated with cancer risk.
|
31759353 |
2019 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The <i>TP53</i> Arg72Pro (rs1042522 C>G) polymorphism has been reported to be associated with the risk of several types of adult cancers; however, its risk for pediatric cancers remains unclear.
|
31293648 |
2019 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
From other HPV-related malignancies a link between a functional SNP in the p53 gene (rs1042522, p.Arg72Pro) and a higher disease risk in the presence of HPV is documented.
|
30519324 |
2018 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Previous studies have indicated that the <i>TP53</i> gene Arg72Pro (rs1042522 C>G) polymorphism is associated with susceptibility to various types of cancer.
|
28275206 |
2017 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
As ionizing radiation (IR) treatment is often used in cancer therapy, we sought to test the physiological effects of IR in mouse models of the p53 R72P polymorphism.
|
28594296 |
2017 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of them, a nonsynonymous polymorphism, Arg72Pro (rs1042522 C>G), has been most extensively studied for the association with cancer risk; however, few studies have investigated its effect on Wilms' tumor.
|
28260929 |
2017 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Risk of cancer</span> specific mortality, cardiovascular mortality, and respiratory mortality were not associated with Arg72Pro genotype overall; however, in exploratory subgroup analyses, genotype-associated risks of malignant melanoma and diabetes were altered.
|
28336930 |
2017 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, increased cancer risks were observed for the TP53 Arg72Pro polymorphism in patients with poorly differential status, clinical stage II, and without lymph node metastasis.
|
26619844 |
2016 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Hence, this study explores the single and combined effects of cancer risk, age of onset and cancer type of three single nucleotide polymorphisms (SNPs)-TP53 Pro72Arg, MDM2 SNP285 and SNP309-already described as modifiers on TP53 mutation carriers but not properly investigated in LFS Suggestive patients.
|
26956143 |
2016 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting.
|
25768405 |
2015 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNPs) of p53 rs1042522, MDM2 rs2279744 and p21 rs1801270, all in the p53 pathway, which plays a crucial role in DNA damage and genomic instability, were reported to be associated with cancer risk and pathologic characteristics.
|
26289323 |
2015 |
rs1042522
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis.
|
26320432 |
2015 |